Infectologia
Estudo de caso-controle | Estimativa da efetividade das vacinas CoronaVac e BNT162b2 em pacientes com a variante Ômicron do SARS-CoV-2
7 Fev, 2023 | 17:46h
Comentário no Twitter
The CoronaVac and BNT162b2 (Pfizer) vaccines were effective against severe outcomes due to Omicron (74-77%), but protection among older individuals in Hong Kong was more likely to wane 6 months after the second dose; boosters can bring effectiveness >90%. https://t.co/kqgwryJ1kT
— JAMA Network Open (@JAMANetworkOpen) February 3, 2023
Diretriz | Diagnóstico e tratamento da otite média efusiva em crianças
7 Fev, 2023 | 15:28h
Taxas de resistência a antibióticos em isolados de Helicobacter pylori nos EUA e na Europa
7 Fev, 2023 | 15:16hComentário: Time to ditch clarithromycin for H. pylori? – MDedge
Comentário no Twitter
New #RedJournal study by Mégraud, et al., shows high antibiotic resistance rates in #Hpylori isolates across the US & EU and the need for antibiotic resistance surveillance and novel treatment strategies for H. pylori.
📕 Read more: https://t.co/JT6P0MnEdW@umfoodoc @cwhowden pic.twitter.com/5FeV3Wj6Dw
— AJG – The American Journal of Gastroenterology (@AmJGastro) November 14, 2022
Painel do FDA direciona-se para vacinas anuais de COVID
31 Jan, 2023 | 12:30hFDA panel eyes shift to annual COVID shots – CIDRAP
Ver também:
FDA advisers recommend updating Covid vaccines – STAT
U.S. Proposes to Make COVID Shot Annual, Much Like Flu Shot – HealthDay
Série de casos | Níveis mais altos de troponina foram associados com lesões cardíacas persistentes em RM em crianças com miocardite após vacinação contra COVID-19 baseada em mRNA
31 Jan, 2023 | 12:27h
Breve revisão e algoritmo | Tratamento da tuberculose latente
23 Jan, 2023 | 13:31hManagement of Latent Tuberculosis Infection – JAMA (gratuito por tempo limitado)
OMS atualiza diretrizes de COVID-19 sobre máscaras, tratamentos e cuidados do paciente
16 Jan, 2023 | 11:17hWHO updates COVID-19 guidelines on masks, treatments and patient care – World Health Organization
Diretrizes OMS atualizadas:
Therapeutics and COVID-19: Living guideline, 13 January 2023 – World Health Organization
Estudo randomizado | Fluvoxamina não é melhor que placebo em pacientes ambulatoriais com COVID-19 leve a moderada
16 Jan, 2023 | 11:12hEditorial: Lack of Benefit of Fluvoxamine for COVID-19 – JAMA
Entrevista com a autora: Fluvoxamine vs Placebo and Time to Sustained Recovery From Mild or Moderate COVID-19 – JAMA
Comentário: Trial finds that fluvoxamine doesn’t speed COVID recovery – CIDRAP
Comentário no Twitter
Among outpatients with mild to moderate #COVID19, treatment with 50 mg of fluvoxamine twice daily for 10 days, compared with placebo, did not improve time to sustained recovery. https://t.co/4QgBssqFSU pic.twitter.com/RMZ6mqlx6u
— JAMA (@JAMA_current) January 12, 2023
Revisão | COVID longa: principais achados, mecanismos e recomendações
16 Jan, 2023 | 11:08hLong COVID: major findings, mechanisms and recommendations – Nature Reviews Microbiology
Conteúdo relacionado: Retrospective Study | Most patients with long Covid developed after mild infection get better within a year
Uma pesquisa sobre a aceitação da vacina contra COVID-19 em 23 países em 2022
16 Jan, 2023 | 11:07hA survey of COVID-19 vaccine acceptance across 23 countries in 2022 – Nature Medicine
Comunicado de imprensa: Global COVID-19 vaccine acceptance rising but hesitancy remains – London School of Hygiene & Tropical Medicine
Comentário no Twitter
The third annual iteration of a survey assessing vaccine confidence in 23 countries shows the overall willingness to accept a COVID-19 vaccine has increased, although results were heteregeous across countries, according to a @NatureMedicine paper. https://t.co/0EkMH7oRdn pic.twitter.com/bLc98F9AYt
— Nature Portfolio (@NaturePortfolio) January 13, 2023